Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPA‐HF</scp>-Reference-Cited by-同舟云学术

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF

Published:2022-02-06 Issue:6 Volume:24 Page:1066-1076
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

McDowell Kirsty¹,Welsh Paul¹,Docherty Kieran F.¹,Morrow David A.²,Jhund Pardeep S.¹,de Boer Rudolf A.³,O'Meara Eileen⁴,Inzucchi Silvio E.⁵,Køber Lars⁶,Kosiborod Mikhail N.⁷⁸,Martinez Felipe A.⁹,Ponikowski Piotr¹⁰,Hammarstedt Ann¹¹,Langkilde Anna Maria¹¹,Sjöstrand Mikaela¹¹,Lindholm Daniel¹¹,Solomon Scott D.²,Sattar Naveed¹,Sabatine Marc S.¹²,McMurray John J.V.¹

Affiliation:

1. BHF Cardiovascular Research Centre University of Glasgow Glasgow UK

2. Cardiovascular Division, Department of Medicine Brigham and Women's Hospital Boston MA USA

3. Department of Cardiology University Medical Center and University of Groningen Groningen The Netherlands

4. Montreal Heart Institute Université de Montréal Montreal Quebec Canada

5. Section of Endocrinology Yale University School of Medicine New Haven CT USA

6. Department of Cardiology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

7. Saint Luke's Mid America Heart Institute University of Missouri Kansas City MO USA

8. The George Institute for Global Health University of New South Wales Sydney New South Wales Australia

9. Universidad Nacional de Córdoba Córdoba Argentina

10. Centre for Heart Diseases, University Hospital Wroclaw Medical University Wroclaw Poland

11. Late Stage Development, Cardiovascular, Renal and Metabolism Biopharmaceuticals R&D, Astrazeneca Gothenburg Sweden

12. TIMI Study Group, Cardiovascular Division Brigham and Women's Hospital, Harvard Medical School Boston MA USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2433

Reference46 articles.

1. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk

2. Uric acid and cardiovascular disease: A clinical review

3. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective

4. Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure

5. Cardiovascular Drugs and Serum Uric Acid

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between gout and subsequent cardiovascular events: a retrospective cohort study with 132,000 using propensity score matching in primary care outpatients in Germany;Clinical Research in Cardiology;2024-09-10

2. Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV;Diabetes, Obesity and Metabolism;2024-09-02

3. Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world;Frontiers in Pharmacology;2024-08-05

4. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy;Cell Reports Medicine;2024-08

5. Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases;Journal of Hypertension;2024-07-10